H-TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU-OH manufacturers
|
| | H-TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU-OH Basic information |
| Product Name: | H-TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU-OH | | Synonyms: | Neuropeptide W-23(human),WYKHVASPRYHTVGRAAGL MGL,NPW-23, >95%;H-TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU-OH;NPW-23 (HUMAN);NEUROPEPTIDE W-23 (HUMAN);TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU;Neuropeptide W-23 (huMan)
NPW-23 (huMan);L-Leucine, L-tryptophyl-L-tyrosyl-L-lysyl-L-histidyl-L-valyl-L-alanyl-L-seryl-L-prolyl-L-arginyl-L-tyrosyl-L-histidyl-L-threonyl-L-valylglycyl-L-arginyl-L-alanyl-L-alanylglycyl-L-leucyl-L-leucyl-L-methionylglycyl-;Neuropeptide W23(human),hypetension,anorexigenic effect,Neuropeptide W 23(human),Neuropeptide W-23 (human),NPW 23,GPR7,Inhibitor,Neuropeptide W,GPR8,NPBW1,NPBW2,inhibit,NPW23 | | CAS: | 383415-79-0 | | MF: | C119H183N35O28S | | MW: | 2584.01 | | EINECS: | | | Product Categories: | Various peptides | | Mol File: | 383415-79-0.mol |  |
| | H-TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU-OH Chemical Properties |
| storage temp. | Desiccate at -20°C | | form | Solid | | color | White to off-white | | Water Solubility | Soluble to 1 mg/ml in sterile water |
| | H-TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU-OH Usage And Synthesis |
| Uses | Neuropeptide W-23 (human) (NPW-23), the active form of Neuropeptide W, is an endogenous agonist of NPBW1 (GPR7) and NPBW2 (GPR8)[1]. | | in vivo | Neuropeptide W-23 (human) (NPW-23) (0.3-3.0 nM; intracerebroventricular injection; 2 μL) increases total behavioral activity, including locomotion and grooming in conscious rats[2].
Neuropeptide W-23 (human) (NPW-23) (2-8 nM; i.c.v.; 10 μL) shows anorexigenic effect in rats[3]. | Animal Model: | Male Harlan Sprague-Dawley rats, 250–300 g[2] | | Dosage: | 0.3, 1.0 and 3.0 nM | | Administration: | Intracerebroventricular injection, 2 μL | | Result: | Caused significant increases in mean arterial pressure. Demonstrated a significant increase in total activity, ambulatory activity, and duration of stereotypy. |
| Animal Model: | Male Wistar rats weighing 250–300 g[3] | | Dosage: | 2, 4, 6 and 8 nM | | Administration: | Intra-cerebroventricular injection, 10 μL | | Result: | Decreased dark feeding and fasting-induced feeding, decreased feeding intake and weight gain. |
| | References | [1] Ji L, et al. Modulation of CaV1.2 calcium channel by neuropeptide W regulates vascular myogenic tone via G protein-coupled receptor 7. J Hypertens. 2015 Dec;33(12):2431-42. DOI:10.1097/HJH.0000000000000723 [2] Pate AT, et al. Neuropeptide W increases mean arterial pressure as a result of behavioral arousal. Am J Physiol Regul Integr Comp Physiol. 2013 Oct 1;305(7):R804-10. DOI:10.1152/ajpregu.00119.2013 [3] Naso T, et al. Central neuropeptide W has anorexigenic effect in rats. J Anim Physiol Anim Nutr (Berl). 2014 Apr;98(2):228-34. DOI:10.1111/jpn.12067 |
| | H-TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU-OH Preparation Products And Raw materials |
|